rxstat › Classes › Antiepileptics

Antiepileptics: shortage status in Canada

10 of the 15 antiepileptics rxstat tracks are currently in shortage in Canada. When one drug in a class is short, demand often shifts to its alternatives, so related drugs can tighten too; each page below shows which manufacturers are affected and the latest recovery estimates.

Oxcarbazepine (Trileptal) Widespread shortage 6 of 8 reported products affected · est. return Oct 18, 2026 Brivaracetam (Brivlera) Partial shortage 2 of 8 reported products affected · est. return Sep 11, 2026 Carbamazepine (Tegretol) Partial shortage 2 of 20 reported products affected Clonazepam (Rivotril) Partial shortage 5 of 21 reported products affected Lacosamide (Vimpat) Partial shortage 7 of 35 reported products affected · est. return Sep 15, 2026 Levetiracetam Partial shortage 12 of 48 reported products affected Phenytoin (Dilantin) Partial shortage 1 of 6 reported products affected Stiripentol (Diacomit) Partial shortage 1 of 1 reported products affected Topiramate (Topamax) Partial shortage 8 of 41 reported products affected · est. return Feb 9, 2027 Valproic Acid (Epival) Partial shortage 4 of 24 reported products affected · est. return Jun 1, 2027 Eslicarbazepine (Aptiom) Shortage anticipated 0 of 4 reported products affected Lamotrigine (Lamictal) No current shortage Perampanel (Fycompa) No current shortage Phenytoin (Dilantin-30) No current shortage Vigabatrin (Sabril) No current shortage

Guides: what to do when your medication is in shortage · how to read these statuses

Class groupings follow the WHO ATC classification in Health Canada's reports. Data reflects manufacturer mandatory filings; see methodology.